Millennium Biotechnologies Receives $705,000 Purchase Order for Resurgex Essential(tm)...

Millennium Biotechnologies Receives $705,000 Purchase Order for Resurgex
Essential(tm) and Resurgex Essential Plus(tm) Ready-to-Drink Products

BASKING RIDGE, N.J., March 24, 2009 (GLOBE NEWSWIRE) -- Millennium
Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies
Group, Inc. (OTCBB: MBTG), a leader in the development, manufacturing and sales
of targeted nutritional products in the Clinical and Sports Nutrition Markets,
announced today that it has received a $705,000 Purchase Order from Provider
Services, Inc. The Purchase Order exclusively requests the delivery of
Millennium's two new Ready-to-Drink product lines Resurgex Essential(tm) and
Resurgex Essential Plus(tm). Millennium will add a new flavor of Resurgex
Essential Plus "Chocolate Truffle," as requested by the customer, in the
upcoming production run at Farmland Dairies.

"We made the transition to Resurgex Essential(tm) and Resurgex Essential
Plus(tm) in order to better meet the critical nutritional needs of our most
important geriatric residents living in our Provider Services community of over
50 facilities and 5,000 beds. Resurgex Essential(tm) and Resurgex Essential
Plus(tm) provide superior ingredients and unique flavor choices as compared to
the competition. These qualities contributed to our decision to make the
Resurgex Essential(tm) product line our nutritional supplementation of choice as
opposed to the competitive products Boost(r), Ensure(r), or other brands.
Naturally our residents will be more compliant in their nutritional regimens
because they enjoy the taste. The increased compliance and enhanced nutritional
value should result in better outcomes in residents as evidenced by improved
weight maintenance, immune support and management of their medical care while
reducing the total cost of care", said Pam Mink, RDLD, Nutrition/Dietary
Consultant for Provider Services, Inc.

"Our transition from a Company which exclusively offered powder-based products,
to a Company which offers ready-to-drink products allowed us to access the
medical institutional long-term care channel. The ready-to-drink products have
been well received by distributors both domestically and internationally. Since
our first commercialized ready-to-drink products went into distribution in the
fourth quarter of 2008 we have received orders for over $1.0MM of ready to drink
product in the first quarter of 2009," said, Mark C. Mirken CEO and Chairman of
the Board.

Mark C. Mirken added, "This success and the overall acceptance and recognized
efficacy of our product now allows us to expand this nutritional product line.
We will now expand the line to diabetic residents, a significantly large and
growing percentage of the elderly population. As our volume increases by
expanding our customer base, we anticipate we will be able to reduce our
manufacturing costs. As a result, we anticipate we will be able to compete on a
retail platform with reduced prices and attract a broader audience."

About Millennium

Millennium's six marketed products form an advanced line of nutritional
formulas. Resurgex Select(r) is a whole foods-based, calorically dense,
high-protein nutritional formula developed for cancer patients undergoing
chemotherapy or radiation treatments. Resurgex(r) and Resurgex Plus(r) are
specialized, anabolic nutritional supplements rich in antioxidants that provide
nutritional support post-treatment. Millennium also created Surgex(tm) sports
nutrition formula to address the nutritional concerns of professional, Olympic,
and amateur elite athletes. These athletes often experience similar symptoms
post-workout to those battling immuno-compromised conditions, such as fatigue,
loss of lean muscle, oxidative stress, and reduced immune function. Resurgex
Essential(tm) and Resurgex Essential Plus(tm) are comprehensive, calorically
dense formulas that meet and succeed the nutritional requirements of the
assisted living community.

Statements in this news release regarding future financial and operating
results, future growth in R&D programs, potential applications of the
Millennium's technology, opportunities for the Millennium, and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements that are not
statements of historical fact (including statements containing the words 'will,'
'believes,' 'plans,' 'anticipates,' 'expects,' 'estimates,' and similar
expressions) should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results or events to
differ materially from those indicated by such forward- looking statements
including: limited operating history, need for future capital, risks inherent in
the development and commercialization of potential products, protection of
Millennium's intellectual property, and economic conditions generally.
Additional information on potential factors that could affect results and other
risks and uncertainties are detailed from time to time in Millennium's periodic
reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the
Securities and Exchange Commission ('SEC'). Millennium Biotechnologies, Inc.

-0-
CONTACT: Millennium Biotechnologies Inc.
Frank Guarino
908-604-2500